CRL:NYE-Charles River Laboratories (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 186.29

Change

+0.90 (+0.49)%

Market Cap

USD 9.50B

Volume

0.23M

Analyst Target

USD 238.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
DHR Danaher Corporation

+1.59 (+0.69%)

USD 165.08B
A Agilent Technologies Inc

+1.50 (+1.11%)

USD 40.09B
IQV IQVIA Holdings Inc

+0.88 (+0.44%)

USD 36.13B
LH Laboratory Corporation of Amer..

+1.65 (+0.72%)

USD 19.12B
DGX Quest Diagnostics Incorporated

+0.48 (+0.31%)

USD 17.09B
QGEN Qiagen NV

+0.24 (+0.54%)

USD 10.26B
VNRX Volitionrx Ltd

+0.04 (+6.56%)

USD 0.06B
ENZ Enzo Biochem Inc

-0.01 (-1.90%)

USD 0.04B
TMO Thermo Fisher Scientific Inc

+3.69 (+0.70%)

N/A
MTD Mettler-Toledo International I..

+11.91 (+0.96%)

N/A

ETFs Containing CRL

HEAL:CA 2.65 % 0.00 %

N/A

N/A
GNRX 0.00 % 0.55 %

N/A

N/A
JSMD Janus Henderson Small/Mid.. 0.00 % 0.50 %

+0.57 (+0%)

USD 0.45B
IS3V:XETRA iShares Global Inflation .. 0.00 % 0.00 %

N/A

USD 0.20B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.20% 15% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.20% 15% F 11% F
Trailing 12 Months  
Capital Gain -21.78% 15% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.78% 15% F 10% F
Trailing 5 Years  
Capital Gain 22.64% 25% F 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.64% 25% F 50% F
Average Annual (5 Year Horizon)  
Capital Gain 14.35% 85% B 74% C
Dividend Return 14.35% 69% C- 70% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 50.61% 8% B- 19% F
Risk Adjusted Return 28.36% 31% F 43% F
Market Capitalization 9.50B 33% F 85% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.